SCHEMBL5637652

SCHEMBL5637652

Clc1cccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCO3)c1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 10/20 0.44
HTR2A P28223 8/20 0.41
HTR2B P41595 3/20 0.41
HTR6 P50406 1/20 0.36
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
DRD2 P14416 4/20 0.33
CHRM1 P11229 3/20 0.32
CHRM3 P20309 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636274 0.91 HTR2C (0.43) HTR2CHTR2AHTR2B
SCHEMBL5635940 0.89 HTR2C (0.42) HTR2CHTR2AHTR2BHTR6DRD2
SCHEMBL5636741 0.88 HTR2C (0.48) HTR2CHTR2AHTR2BHTR6DRD2
SCHEMBL5637783 0.87 HTR2C (0.49) HTR2CHTR2AHTR2BHTR6DRD2
SCHEMBL5636755 0.87 HTR2C (0.41) HTR2CHTR2AHTR2BSMN1; SMN2
SCHEMBL5637941 0.86 HTR2C (0.45) HTR2CHTR2AHTR2BDRD2CHRM1
SCHEMBL5636639 0.85 HTR2C (0.48) HTR2CHTR2AHTR2BHTR6SMN1; SMN2
SCHEMBL5636217 0.85 HTR2C (0.40) HTR2CHTR2AHTR2BHTR6CHRM1
SCHEMBL5636911 0.84 HTR2C (0.47) HTR2CHTR2AHTR2BDRD2
SCHEMBL5637932 0.84 HTR2C (0.43) HTR2CHTR2AHTR2BHTR6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed